Brought to you by 
Amgen acquires Avidia for $290mm plus $90mm earn-out
Oct 2006
Executive Summary
Amgen has agreed to acquire the 96% of Avidia (developing therapeutics for inflammation, autoimmune diseases, cancer, and neurological conditions) that it does not already own for $290mm up front, plus two potential earn-outs--based on the development of certain compounds--that could total up to $90mm. Avidia, a Maxygen spin-off, will now be a wholly owned subsidiary of Amgen.
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Full Acquisition
- Acquisition of Private Biotech
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com